Semantic Scholar uses AI to extract papers important to this topic.
Preclinical data suggest that EGFR tyrosine kinase inhibitors (TKIs) plus MET TKIs are a possible treatment for EGFR… Expand Importance
Papillary renal cell carcinoma (PRCC) is the most common type of non-clear cell RCC. Because some cases of PRCC are… Expand Purpose: Aberrant activation of MET (hepatocyte growth factor receptor) signaling is implicated in the tumorigenesis of human… Expand First generation or second generation EGFR tyrosine kinase inhibitors are currently the standard of care for the first-line… Expand Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited therapeutic options. PRCC may involve… Expand Lung cancer is the most common cause of cancer death globally with a significant, unmet need for more efficacious treatments. The… Expand 2509 Background: AZD9291 is an irreversible, mutant-selective EGFR tyrosine kinase inhibitor (TKI) developed to have potency… Expand Purpose: Papillary renal cell carcinoma (PRCC) is the second most common cancer of the kidney and carries a poor prognosis for… Expand Background: Volitinib is a selective oral small molecule inhibitor of cMet kinase, which has demonstrated potent in vivo… Expand 487 Background: Met is a receptor tyrosine kinase that is deregulated across multiple cancer types, leading to uncontrolled tumor… Expand